Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Industry CEOs Are Taking “Positive” Steps On GMPs, FDA’s Galson Says

This article was originally published in The Tan Sheet

Executive Summary

FDA's discussions with pharmaceutical industry CEOs over the past year give the agency confidence that manufacturing quality is improving, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Schwab Washington Research Group conference May 2

You may also be interested in...

FDA PAT Inspection Teams Being Formed: Further Training Set For Fall

FDA is assembling review/inspection teams to help evaluate upcoming industry submissions involving implementation of process analytical technologies in manufacturing

FDA/Industry Manufacturing Approach Is “Suboptimal” – CDER’s Woodcock

FDA is ready to change the current model of manufacturing oversight and enforcement, Center for Drug Evaluation & Research Director Janet Woodcock, MD, indicated during the recent Lehman Brothers Global Healthcare Conference in Orlando

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts